Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study

Am J Hematol. 2023 Dec;98(12):E349-E353. doi: 10.1002/ajh.27071. Epub 2023 Aug 30.

Adrien Contejean¹, Cécile Janssen², Frédérique Orsini-Piocelle¹, Céline Zecchini³, Caroline Charlier^{4

5

6

7}, Laurent Chouchana⁸

¹ Service d'Hématologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.
² Service d'Infectiologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.
³ Pharmacie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.
⁴ Université Paris Cité, Paris, France.
⁵ Equipe Mobile d'Infectiologie, CHU Cochin, AP-HP Centre, Paris, France.
⁶ Institut Pasteur, French National Reference Center and WHO Collaborating Center Listeria, Paris, France.
⁷ Institut Pasteur, Biology of Infection Unit, Inserm U1117, Paris, France.
⁸ Centre régional de Pharmacovigilance, Département de Pharmacologie, CHU Cochin, AP-HP Centre, Paris, France.

No abstract available

Publication types